Tezspire Cardiac Events PASS
← catalyst calendarNCT06951867 · readout in 1,016 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With IQVIA Pvt. Ltd.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
16,640estimated
Sites
4
Countries
Denmark, France, Germany +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-09-15 | actual | When the study began enrolling |
| Primary completion | 2029-05-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-05-31 | estimated | The whole study's end, after follow-up |
| First posted | 2025-04-30 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Cardiovascular Events
- MACE
Intervention
- Drug: Tezepelumab — also filed as TEZSPIRE
Primary outcome
what the primary-completion date above is the date OFcomposite outcome MACE
measured five years from tezepelumab market launch
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed